Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …

Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …

Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …

Autologous chimeric antigen receptor (CAR) T cell therapies targeting CD19 have high
efficacy in large B cell lymphomas (LBCLs), but long-term remissions are observed in less …

Profiling of circulating tumor DNA (ctDNA) in the bloodstream shows promise for
noninvasive cancer detection. Chromatin fragmentation features have previously been …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

The scarcity of malignant Hodgkin and Reed–Sternberg cells hampers tissue-based
comprehensive genomic profiling of classic Hodgkin lymphoma (cHL). By contrast, liquid …

Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of …

Next-generation DNA sequencing technology has dramatically advanced clinical oncology
through the identification of therapeutic targets and molecular biomarkers, leading to the …

PURPOSE Clinical outcomes of patients with CNS lymphomas (CNSLs) are remarkably
heterogeneous, yet identification of patients at high risk for treatment failure is challenging …